Application of texture signatures based on multiparameter-magnetic resonance imaging for predicting microvascular invasion in hepatocellular carcinoma: Retrospective study

Table 3 The misjudgment rate (%) of magnetic resonance image-based texture analysis

MR image	Project	Fisher	POE + ACC	MI	MI + PA + F
T2WI	RDA	57/105 (or 54.29)	57/105 (or 54.29)	59/105 (or 56.19)	50/105 (or 47.62)
	PCA	52/105 (or 49.52)	57/105 (or54.29)	57/105 (or 54.29)	58/105 (or 55.24)
	LDA	46/105 (or 43.81)	46/105 (or43.81)	47/105 (or 44.76)	34/105 (or 32.38)
	NDA	26/105 (or 24.76)	27/105 (or25.71)	29/105 (or 27.62)	24/105 (or 22.86)
Arterial phase	RDA	44/105 (or 41.90)	52/105 (or49.52)	38/105 (or 36.19)	49/105 (or 46.67)
	PCA	46/105 (or 43.81)	52/105 (or49.52)	39/105 (or 37.14)	49/105 (or 46.67)
	LDA	41/105 (or 39.05)	36/105 (or34.29)	46/105 (or 43.81)	34/105 (or 32.38)
	NDA	22/105 (or 20.95)	23/105 (or21.90)	25/105 (or 23.81)	17/105(or16.19))
Portal phase	RDA	41/105 (or 39.05)	46/105 (or43.81)	48/105 (or 45.71)	38/105 (or 36.19)
	PCA	41/105 (or 39.05)	41/105 (or39.05)	48/105 (or 45.71)	38/105 (or 36.19)
	LDA	45/105 (or 42.86)	48/105 (or45.71)	42/105 (or 40.00)	32/105 (or 30.48)
	NDA	32/105 (or 30.48)	28/105 (or26.67)	33/105 (or 31.43)	22/105 (or 20.95)
Equilibrium period	RDA	43/105 (or 40.95)	56/105 (or53.33)	42/105 (or 40.00)	48/105 (or 45.71)
	PCA	42/105 (or 40.00)	55/105 (or52.38)	45/105 (or 42.86)	42/105 (or 40.00)
	LDA	49/105 (or 46.67)	42/105 (or40.00)	45/105 (or 42.86)	34/105 (or 32.38)
	NDA	28/105 (or 26.67)	23/105 (or21.90)	27/105 (or 25.71)	22/105 (or 20.95)

MR: Magnetic resonance; RDA: Redundancy Analysis; PCA: Principal Component Analysis; LDA: Linear Discriminant Analysis; NDA: Non- Linear Discriminant Analysis; T2WI: T2-weighted imaging.